 |
Sino-American Agreement on New Medicine for Rheumatoid Arthritis.
A Sino-American agreement was signed Wednesday in Shijiazhuang, capital of north China's Hebei Province, concerning the technological development of PX3 -- a new medicine for rheumatoid arthritis.
The Jintansheng Biological Technology Development Company of the North China Pharmaceutical Group Corporation (NCPGC) in the province and the Pan-Pacific Pharmaceutical Ltd. at Stanford University's high-tech development zone will jointly carry out the new development project for the medicine.
Statistics show that about 1 percent of the world's population, including 10 million people in China, are suffering from rheumatoid arthritis.
Every year, the medical costs that come with treating the disease is about 100 billion US dollars worldwide. So far, no medicine with a good effect has been developed for rheumatoid arthritis patients.
As China's largest State-owned pharmaceutical enterprise, NCPGC initiated research and development in biological medicine 20 years ago.
In This Section
|